GMP under the FDA lives in 21 CFR Parts 210 and 211. The text is dense, the implementation is operational, and the practical experience of GMP shows up in dozens of small daily decisions on a factory floor. This is the practical guide to what those parts actually require.
21 CFR Part 210: the foundation
Part 210 lays out the minimum current Good Manufacturing Practice for the manufacturing, processing, packing, or holding of drugs. It's the umbrella that gives the rest of the regulation its scope.
The key principle: every drug product has to be manufactured under conditions that ensure identity, strength, quality, and purity. That sounds vague. Part 211 fills in the specifics.
21 CFR Part 211: where it gets specific
Part 211 is structured by topic. The sections that matter most in daily operation:
Subpart B - Organization and Personnel. Defines the role of the quality unit (independent of production, with authority to release or reject batches). Defines training requirements for everyone who touches a regulated process.
Subpart C - Buildings and Facilities. Cleanroom design, cross-contamination prevention, environmental controls. The specifics that determine whether your facility can be built where you want.
Subpart D - Equipment. Equipment qualification (IQ, OQ, PQ), cleaning protocols, calibration. The requirements that drive how you select and validate every machine on the floor.
Subpart E - Control of Components. Raw material handling, sampling, testing, release. The traceability chain that lets you reconstruct any batch.
Subpart F - Production and Process Controls. Batch records, in-process testing, written procedures. The documentation backbone of everything that happens.
Subpart G - Packaging and Labeling. The specific subpart that governs our world. Packaging operations, label control, finished product handling.
Subpart H - Holding and Distribution. Warehouse conditions, distribution records, quarantine.
Subpart I - Laboratory Controls. Test methods, stability programs, retention samples.
Subpart J - Records and Reports. The retention and accessibility requirements for everything you've documented.
What an FDA inspector actually looks at
Inspectors don't read all of 211 against your facility. They sample. The patterns that turn up most often in 483 observations:
Inadequate batch records. Records that don't support reconstruction of the batch, missing signatures, incomplete deviation entries.
Cleaning validation gaps. No documented evidence that the cleaning protocol removes residues to acceptable limits, or evidence that's stale.
Training records out of date. Operators on the line whose retraining is overdue.
Deviation handling. Deviations not escalated, not investigated, not closed within a defined timeframe.
Environmental monitoring. Cleanroom data that doesn't show consistent control, or trending that's been ignored.
The packaging-specific GMP angle
In our world, the most-cited GMP findings are around label control and serialization. Mixed labels between batches, missing 2D Data Matrix codes, label artwork changes that didn't go through change control. All catchable, all preventable.
We run a label control system that scans every label against the batch master before it goes on a wallet. If they don't match, the line stops. That kind of front-loaded prevention is what keeps GMP findings off our inspection record.
If you're picking a GMP-compliant packer
Don't ask whether they're GMP-certified. Everyone says yes. Ask for the most recent FDA Form 483 or EMA inspection report. Ask how many observations they took. Ask which subparts they were cited under and what corrective action they implemented.
A clean recent record matters more than a current certificate. Drop us a line if you want to see ours.
Request a free sample now!
